D’Haens, G. et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn’s disease: an open randomised trial. Lancet 371, 660–667 (2008).

Article  PubMed  Google Scholar 

Colombel, J.-F. et al. Effect of tight control management on Crohn’s disease (CALM): a multicentre, randomised, controlled phase 3 trial. Lancet 390, 2779–2789 (2017).

Article  PubMed  Google Scholar 

D’Haens, G. R. et al. Vedolizumab treatment is more effective and safer in early versus late Crohn’s disease: final results of the Love-CD trial. United European Gastroenterol. J. 12, OP147 (2024).

Google Scholar 

Sands, B. E. et al. Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn’s disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial. Lancet 399, 2200–2211 (2022).

Article  CAS  PubMed  Google Scholar 

Ponsioen, C. Y. et al. Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn’s disease: a randomised controlled, open-label, multicentre trial. Lancet Gastroenterol. Hepatol. 2, 785–792 (2017).

Article  PubMed  Google Scholar 

Stevens, T. W. et al. Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn’s disease: retrospective long-term follow-up of the LIR!C trial. Lancet Gastroenterol. Hepatol. 5, 900–907 (2020).

Article  PubMed  Google Scholar 

Schreiber, S. et al. Subgroup analysis of the placebo-controlled CHARM trial: increased remission rates through 3 years for adalimumab-treated patients with early Crohn’s disease. J. Crohns Colitis 7, 213–221 (2013).

Article  CAS  PubMed  Google Scholar 

Cozijnsen, M. A. et al. Top-down infliximab study in kids with Crohn’s disease (TISKids): an international multicentre randomised controlled trial. BMJ Open Gastroenterol. 3, e000123 (2016).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Noor, N. M. et al. A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn’s disease (PROFILE): a multicentre, open-label randomised controlled trial. Lancet Gastroenterol. Hepatol. 9, 415–427 (2024).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Revés, J. et al. Early biological therapy within 12 months of diagnosis leads to higher transmural healing rates in Crohn’s disease. Clin. Gastroenterol. Hepatol. https://doi.org/10.1016/j.cgh.2024.07.034 (2024).

Article  PubMed  Google Scholar